Abstract: The disclosure provides methods for isolating nucleic acids from a biological fluid. In one aspect, the disclosure provides a method for isolating RNA. In another aspect, the disclosure provides a method for isolating DNA. In one aspect, the methods described herein utilize a protocol that combines a detergent-based initial denaturation, protease digestion, and organic extraction followed by column purification that maximizes RNA/DNA yield and preserves RNA/DNA integrity. In yet another aspect, the disclosure provides a kit for isolating RNA and/or DNA.

Abstract: The disclosure provides methods for isolating nucleic acids from a biological fluid. In one aspect, the disclosure provides a method for isolating RNA. In another aspect, the disclosure provides a method for isolating DNA. In yet another aspect, the disclosure provides a kit for isolating RNA and/or DNA.

Abstract: The level of miRNAs in a sample from a patient is assayed and used as an indicator of the efficacy of a therapeutic intervention for a cardiovascular disease, such as heart failure. The levels of a plurality of miRNAs, such as myomirs, may be measured. Based on the measured level of the miRNAs, the therapeutic intervention may be modified, adjusted, continued or discontinued. The miRNA level may also be used to assess the severity or disease progression of a cardiovascular disease.